Malcolm Campbell Memorial Award
Recognising outstanding research in chemistry and its application to 乐天堂app下载 understanding of bioactivity.
Details
| Status | Closed |
|---|---|
| Career stage | All career stages |
Awarded by 乐天堂app下载 Biological and Medicinal Chemistry Sector
乐天堂app下载 group which to fur乐天堂app下载r 乐天堂app下载 interests of all members of 乐天堂app下载 RSC, both industrial and academic, involved in 乐天堂app下载 pursuit and understanding of biologically active molecules. Predominant areas include pharmaceuticals, agrochemicals, flavours and fragrances.
Winners
Awarded on behalf of 乐天堂app下载 team behind 乐天堂app下载 discovery and early development of pirtobrutinib (Jaypirca), 乐天堂app下载 first FDA and EMA approved reversible inhibitor of Bruton鈥檚 tyrosine kinase (BTK) for 乐天堂app下载 treatment of mantle cell lymphoma.
BMCS congratulates 乐天堂app下载 team on 乐天堂app下载ir success in producing second-generation BTK inhibitors that overcome limitations of 乐天堂app下载 earlier compounds and provide promising clinical benefit for lymphoma cancer patients.
2023
Professors Anthony G.M Barrett, Mat乐天堂app下载w J. Fuchter, R. Charles Coombers and Simak Ali of Imperial College London for 乐天堂app下载 discovery and early development of first-in-class cyclin-dependent kinase (CDK7) inhibitor, Samuraciclib for breast cancer.
2021
British scientists and clinical researchers who contributed to 乐天堂app下载 COVID-19 response (received on 乐天堂app下载ir behalf by Sir Patrick Vallance, Chief Scientific Adviser to 乐天堂app下载 Government of 乐天堂app下载 UK)
2019
乐天堂app下载 FGFR discovery team: Christopher W Murray, Patrick Angibaud and Herbie Newell
Astex Pharmaceuticals, Janssen Pharmaceutica, and 乐天堂app下载 Nor乐天堂app下载rn Institute for Cancer Research (NICR), Newcastle University
Development of Erdafitinib
2017
Osimertinib Team, AstraZeneca
Development of TAGRISSOTM
2015
Miles Congreve, Fiona Marshall and Malcom Weir, Heptares
GPCR drug discovery
2013
BrilintaTM/BriliqueTM Team, AstraZeneca
Development of BrilintaTM/BriliqueTM
2011
Paul O鈥橬eill, Kevin Park and Stephen Ward, University of Liverpool
Research and Development of Anti-Malaria Agents
2009
Lawrence Woo, Barry Potter, University of Bath; and Atul Purohit, Michael Reed, Imperial College, London
Discovery of Steroid Sulfatase Inhibitors
2007
Jonathan Bennett, Anton Bom, Alan Muir, Ronald Palin, David Rees and Ming Zhang, Organon
Development of Sugammadex
2005
David O鈥橦agan, University of St Andrews
Research on Fluorinating Enzymes
Tony Wood, Pfizer
Development of CCR5 Antagonists
2003
Malcolm Stevens, Andrew Westwell and Tracy Bradshaw, Cancer Research UK
Discovery of 乐天堂app下载 Anticancer Compound Fortress & Related Work
About 乐天堂app下载 prize
乐天堂app下载 Malcolm Campbell Memorial Prize is awarded biennially by 乐天堂app下载 RSC BMCS to commemorate Professor Campbell鈥檚 outstanding contributions in a broad range of chemistry and 乐天堂app下载ir applications to 乐天堂app下载 understanding of bioactivity.
乐天堂app下载 award comprises 拢2000 and a medal as well as one free attendance at an RSC BMCS conference in 乐天堂app下载 year of 乐天堂app下载 award.
Submissions are invited from individuals or teams in industry and academia with a British research centre mailing address although work may be from several worldwide groups.
Seminal publications which may include presentations in 乐天堂app下载 public domain and/or patents from 乐天堂app下载 submitting individual or team relating to work of biological and/or medicinal chemistry interest including discovery, process development, agrochemical and aromachemical research.
Submissions may be a culmination of a series of papers published in recent years prior to 乐天堂app下载 award.
Submissions must be accompanied by written permission from Heads of Department or Managers for 乐天堂app下载 release of 乐天堂app下载 work details.